For over 20 years, INOVA has produced innovative, autoimmune disease assays using both novel and “time-tested” methodologies with the single purpose of producing better clinical results to aid patient diagnosis and care.
The key to autoimmune disease diagnostics is presenting an antigen in a configuration where it immunologically binds “clinically significant” autoantibodies associated with a particular disease, and which can be separated and measured. The best antigen maintains the antigenic configuration or epitopes that bind disease-specific autoantibodies with high clinical sensitivity and specificity, once incorporated into the immunoassay.
INOVA has the expertise and capability to prepare and choose the best antigens for the specific assay among native, recombinant or synthetic peptide sources. The optimal antigen for each assay is chosen for clinical suitability by comparing various antigens against clinically characterized specimens, and has a long history of further validating that choice in clinical studies.
Research, product development and manufacturing groups are vertically integrated allowing INOVA to maintain high quality standards by producing key raw materials, purifying native antigens or internally producing recombinant and synthetic peptide antigens using a host of technologies and techniques.
While INOVA’s past 20 years have seen exciting innovation, it’s clear that the coming decades will hold even greater promise for new autoimmune disease diagnostic solutions with INOVA leading the way.
THINK INNOVATION. THINK INOVA.